Phase 4: Therapeutic dose (Weeks 13-16) Dose: 8 mg or 9 mg once weekly What to expect: Strong appetite suppression Significant ongoing weight loss Possible temporary GI flare during escalation Many reach 10-15% weight loss by this phase Tips: This is where most people stabilize 8 mg may be sufficient for manyhigher isn't always better Continue lifestyle optimization Regular check-ins with healthcare provider Phase 5: Maximum dose (Week 17+) Dose: 12 mg once weekly (if tolerated and needed) What to expect: Maximum therapeutic effect Continued weight loss (averaging 20%+ by 48 weeks in trials) GI side effects may be manageable or may persist Some achieve 25-30%+ weight loss Tips: Not everyone needs to reach 12 mg Lower doses may provide sufficient results Balance efficacy with tolerability Maintenance may involve dose reduction For general peptide dosing principles, see our peptide dosage calculator guide
GLP1R agonists increase heart rate and might not be beneficial in individuals with severe left ventricular dysfunction, reduced ejection fraction and/or a history of repeated hospitalization for heart failure
Obesity, insulin resistance, diabetes and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity and Metabolism)
Medical-grade skincare helps strengthen the barrier, support collagen-building actives, and protect against UV-driven collagen breakdown
Your provider will recommend the appropriate starting dose and adjust gradually based on your response and lab monitoring to support safe, sustainable progress
5 Conclusion DM as a major challenge in global public health, is showing a serious trend of increasing prevalence year by year
